Double hit lymphoma: from biology to therapeutic implications.

abstract：INTRODUCTION:Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has shown superiority as compared to available conventional chemotherapies, in terms of reduction in splenomegaly and improvement of symptoms and quality of life. Areas covered: Data published about overall survival in the major randomized spon...

journal_title：Expert review of hematology

authors： Massaro F,Molica M,Breccia M

更新日期：2017-02-01 00:00:00

abstract：INTRODUCTION:Most patients with Hodgkin lymphoma (HL) enjoy durable remissions following front-line treatment but 30% of patients are refractory or relapse after first line therapy. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) can cure an additional 50-55% of relapsing patients but new t...

journal_title：Expert review of hematology

authors： Donato EM,Fernández-Zarzoso M,De La Rubia J

更新日期：2017-05-01 00:00:00

abstract：INTRODUCTION:Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology. New agents increase the complexit...

journal_title：Expert review of hematology

authors： Chihara D,Kreitman RJ

更新日期：2020-10-01 00:00:00

abstract：:It is well known that the risk of venous thromboembolism is increased after surgery; however, specific data on how long this risk lasts or how the risk varies by type of surgery is limited. The Million Women Study is a population-based prospective study that recruited 1.3 million women through the National Health Serv...

journal_title：Expert review of hematology

authors： Faltas B

更新日期：2010-04-01 00:00:00

abstract：:Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

journal_title：Expert review of hematology

authors： Al-Hussaini M,DiPersio JF

更新日期：2014-08-01 00:00:00

abstract：INTRODUCTION:Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. As a result, there is widespread variation in the interpretation and implementation of these guidelines. Areas covered: This review will cover: th...

journal_title：Expert review of hematology

authors： Cavo M,Terpos E,Bargay J,Einsele H,Cavet J,Greil R,de Wit E

更新日期：2018-03-01 00:00:00

abstract：:Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct...

journal_title：Expert review of hematology

authors： Figueiredo L,Cole PD,Drachtman RA

更新日期：2016-03-01 00:00:00

abstract：:Adult immune thrombocytopenia was previously considered a benign disease affecting young people and with a low risk of severe bleeding. This view was challenged by studies published during the past decade, as the median age of adult immune thrombocytopenia patients has been found to be 55-60 years and the incidence in...

journal_title：Expert review of hematology

authors： Frederiksen H,Christiansen CF,Nørgaard M

更新日期：2012-04-01 00:00:00

abstract：:Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause diff...

journal_title：Expert review of hematology

authors： Radia R,Pamphilon D

更新日期：2011-04-01 00:00:00

abstract：INTRODUCTION:Immune surveillance is the dynamic process whereby the immune system identifies and kills tumor cells based on their aberrant expression of stress-related surface molecules or presentation of tumor neoantigens. It plays a crucial role in controlling the initiation and progression of hematologic cancers suc...

journal_title：Expert review of hematology

authors： Nesic M,El-Galaly TC,Bøgsted M,Pedersen IS,Dybkær K

更新日期：2020-06-01 00:00:00

abstract：:Recombinant IFN-α (rIFN-α) induces complete hematologic remissions in patients with myeloproliferative neoplasms (MPNs), but its use has been limited by side effects owing to the relatively high doses used. Now, low-dose rIFN-α is stressed, starting relatively early in the course of the MPNs. In polycythemia vera, thi...

journal_title：Expert review of hematology

authors： Silver RT,Kiladjian JJ,Hasselbalch HC

更新日期：2013-02-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation is still the only potentially curative treatment for patients with myelodysplastic syndromes. Improvements in donor selection, supportive care and the introduction of reduced-intensity conditioning have led to a decrease in early transplant mortality. However, relapse...

journal_title：Expert review of hematology

authors： Sockel K,Ehninger G,Hofbauer LC,Platzbecker U

更新日期：2011-12-01 00:00:00

abstract：:Major advances have significantly improved the outcome of mantle cell lymphoma (MCL). Incorporation of rituximab to CHOP regimen, the adoption of high dose cytarabine with frontline autologous stem cell transplantation in young patients, maintenance rituximab or bortezomib based chemotherapy in elderly patients, impro...

journal_title：Expert review of hematology

authors： El Halabi L,Ghez D,Ribrag V

更新日期：2016-03-01 00:00:00

abstract：INTRODUCTION:In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab a...

journal_title：Expert review of hematology

authors： Brioli A,Mügge LO,Hochhaus A,Von Lilienfeld-Toal M

更新日期：2017-03-01 00:00:00

abstract：:Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is ...

journal_title：Expert review of hematology

authors： Grosicki S

更新日期：2015-06-01 00:00:00

abstract：:Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to acute myeloid leukemia. Deletion of the long arm of chromosome 5 (del(5q)) is the most common clonal chromos...

journal_title：Expert review of hematology

authors： Gorshein E,Weber UM,Gore S

更新日期：2020-03-01 00:00:00

abstract：:Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count that has persisted for more than 12 months. Patients with severe, symptomatic disease may have significant morbidity and require treatment. Historically, the underlying cause of ITP was believed to be accelerated plat...

journal_title：Expert review of hematology

authors： Cheng G

更新日期：2011-06-01 00:00:00

abstract：:Despite significant improvements in treatment modalities over the 10 years, the clinical course of patients with follicular lymphoma (FL) remains heterogeneous. Thus, prognostic indexes are still required to direct treatment choices and for the design of clinical trials. Investigators have conducted a variety of studi...

journal_title：Expert review of hematology

authors： Luminari S,Cox MC,Montanini A,Federico M

更新日期：2009-10-01 00:00:00

abstract：:Tumor lysis syndrome (TLS) is a rare but potentially life-threatening complication of neoplasms, preferentially hematological malignancies. Well known since at least ninety years ago, this condition can be misdiagnosed and incorrectly managed due to rapid onset of symptoms, sometimes overlapping with cancer-derived cl...

journal_title：Expert review of hematology

authors： Criscuolo M,Fianchi L,Dragonetti G,Pagano L

更新日期：2016-01-01 00:00:00

abstract：:Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy. Methods to improve mobilization efficiency and yields are rapidly emerging. Traditional methods include chemotherapy with or without myeloid growth factors. Plerixafor, a...

journal_title：Expert review of hematology

authors： Damon LE,Damon LE

更新日期：2009-12-01 00:00:00

abstract：:The introduction of bortezomib, a first-generation proteasome inhibitor, changed the standard-of-care for newly diagnosed and relapsed multiple myeloma patients. The next generation of proteasome inhibitors, such as carfilzomib, provides a novel pharmacokinetic and pharmacodynamic profile. In vitro data suggest a more...

journal_title：Expert review of hematology

authors： Khan RZ,Badros A

更新日期：2012-08-01 00:00:00

abstract：:In chronic lymphocytic leukemia (CLL), the most prevalent lymphoid malignancy in western countries, patients have a median age at diagnosis of 72 years. In the last few years, there has been remarkable progress in understanding the biology of CLL, the detection of molecular prognostic factors and the development of mo...

journal_title：Expert review of hematology

authors： Molica S,Brugiatelli M,Morabito F,Ferrara F,Iannitto E,Di Renzo N,Capalbo S,Musto P,Di Raimondo F

更新日期：2013-08-01 00:00:00

abstract：INTRODUCTION:The most common forms of hematological malignancies that occur in female reproductive years are lymphoma and leukemia. Areas covered: Several aggressive gonadotoxic regimens such as alkylating chemotherapy and total body irradiation are used frequently in treatment of lymphoma and leukemia leading to subse...

journal_title：Expert review of hematology

authors： Salama M,Isachenko V,Isachenko E,Rahimi G,Mallmann P

更新日期：2017-11-01 00:00:00

abstract：INTRODUCTION:Iliopsoas muscle hemorrhage in patients with hemophilia is a serious complication with relevant related morbidity. AREAS COVERED:A Cochrane Library and PubMed (MEDLINE) search of studies related to iliopsoas hematomas in hemophilia was analyzed. Pain in the hip joint area and femoral nerve involvement in ...

journal_title：Expert review of hematology

authors： Rodriguez-Merchan EC,De la Corte-Rodriguez H

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:The discovery of the factor V Leiden (FVL) missense mutation (Arg506Gln) causing factor V resistance to the anticoagulant action of activated protein C was a landmark that allowed a better understanding of the basis of inherited thrombotic risk. FVL mutation is currently the most common known hereditary de...

journal_title：Expert review of hematology

authors： Campello E,Spiezia L,Simioni P

更新日期：2016-12-01 00:00:00

abstract：:Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondapar...

journal_title：Expert review of hematology

authors： Rachidi S,Aldin ES,Greenberg C,Sachs B,Streiff M,Zeidan AM

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Hb H disease is an alpha-thalassemia (α-thal) syndrome characterized by chronic hemolytic anemia that occurs when three of total four α-globin genes lost their function due to completely deletions or different kind of mutations. OBJECTIVE:We here described 66 patients who have been diagnosed for Hb H diseas...

journal_title：Expert review of hematology

authors： Farashi S,Bayat N,Vakili S,Faramarzi Garous N,Ashki M,Imanian H,Najmabadi H,Azarkeivan A

更新日期：2016-01-01 00:00:00

abstract：:Introduction: The purpose of this article is to review which data about hemophilia are currently provided by the Cochrane database of systematic reviews (CDBSR). Methodological consideration: All statements about hemophilia in the Cochrane Collaboration are based on evidence generated in randomized controlled clinical...

journal_title：Expert review of hematology

authors： Rodriguez-Merchan EC

更新日期：2019-11-01 00:00:00

abstract：:Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic u...

journal_title：Expert review of hematology

authors： Aledort L,Ljung R,Mann K,Pipe S

更新日期：2014-06-01 00:00:00

abstract：INTRODUCTION:Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder that has become the neoplastic poster child for understanding the disease biology of a malignant disease and targeting effective therapy. The targeted therapy of BCR-ABL inhibition by tyrosine kinase inhibitors (TKI) has provided the epitome f...

journal_title：Expert review of hematology

authors： Poch Martell M,Sibai H,Deotare U,Lipton JH

更新日期：2016-10-01 00:00:00